CAPR SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 14, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 13, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 17, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 10, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 11, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 14, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Capricor Therapeutics Announces Extension of PDUFA Target Action Date for Deramiocel BLA

Aug 24, 2026

8-K

Capricor Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update

Aug 13, 2026

8-K

FDA Advisory Committee Votes Against Effectiveness of Deramiocel for DMD Cardiomyopathy

Jul 30, 2026

8-K

The Lancet Publishes HOPE-3 Phase 3 Clinical Trial Results for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy

Jul 29, 2026

8-K

Capricor Therapeutics Enters Lease Agreement for New San Diego Headquarters

Jul 14, 2026

8-K

Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

Jun 26, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

REGISTERED OFFERING

Dec 5, 2025

424B3

UPDATED | ATM | Offering amount: $125,000,000 | Amount sold to date: $2,682,307

Dec 5, 2025

424B5

PENDING FIXED PRICE OFFERING | Bank: Piper Sandler, Oppenheimer & Co.

Dec 4, 2025

424B5

SHELF OFFERING | Shares amount: 4,412,000 | Share price: $17.00 | Offering amount: $75,004,000.00 | Bank: Piper Sandler Oppenheimer & Co.

Oct 17, 2024

424B5

PENDING OFFERING | Bank: Piper Sandler Oppenheimer & Co.

Oct 16, 2024

424B5

Sep 29, 2023

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Jan 30, 2026

S-3

September 2025 SHELF & ATM

Sep 10, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Jun 16, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Feb 5, 2025

S-3

SHARE RESALE REGISTRATION | Shares amount: 2,798,507 | Share price: $5.36 EFFECTIVE

Oct 22, 2024

S-3/A

SHELF | Offering amount: $150,000,000.00 EFFECTIVE

Oct 16, 2024

Proxies

TYPE

HEADLINE

FILED AT

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 10, 2026

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Mar 31, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 8, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Mar 29, 2024

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Mar 20, 2024

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 17, 2023

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13G/A

MILLENNIUM MANAGEMENT LLC (Filed by)

Oct 14, 2026

SCHEDULE 13G

MILLENNIUM MANAGEMENT LLC (Filed by)

Sep 14, 2026

SCHEDULE 13G

MILLENNIUM MANAGEMENT LLC (Filed by)

Aug 19, 2026

SCHEDULE 13G/A

TANG CAPITAL MANAGEMENT LLC (Filed by)

Aug 14, 2026

SCHEDULE 13G

STATE STREET CORP (Filed by)

Aug 7, 2026

SCHEDULE 13G

RA CAPITAL MANAGEMENT, L.P. (Filed by)

Aug 3, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Sep 24, 2025

CORRESP

Form CORRESP - Correspondence

Sep 19, 2025

LETTER

Form UPLOAD - SEC-generated letter

Sep 16, 2025

EFFECT

Form EFFECT - Notice of Effectiveness

Nov 12, 2024

CORRESP

Form CORRESP - Correspondence

Nov 6, 2024

LETTER

Form UPLOAD - SEC-generated letter

Oct 28, 2024

Capricor Therapeutics, Inc. CAPR · SEC Filings